Public Goods, NIH Funding, and Civic Literacy

    loading  Checking for direct PDF access through Ovid

Excerpt

There have been recent debates about reductions to federal funding for biomedical research. The President’s 2017 proposed budget will cut funding to the National Institutes of Health by 18% with pledges to reorganize the 27 institutes and address perceived mission creep.1 These debates are important; the questions on the table for consideration require hard choices and the potential gains and losses can have profound effects on our nation’s health and well-being, our current and future prosperity, and even the readiness of our national defense. Moreover, the information required to make good decisions is incomplete and the consequences of our choices complex and difficult to fully anticipate. The point of this editorial is to help inform this debate by shedding some light on the products of our national investment in health research as well as the stewardship of those investments, i.e. what do we get for this investment and how do we get it. In the interest of full disclosure, I am funded, in part, by the National Eye Institute to conduct research (R01EY022362).
Let us begin with a refresher on the basic economics of public goods. Public goods are goods or services that are different from traditional goods and services because their consumption does not reduce their availability to others. Examples include national defense, tissue culture, development of a new surgical procedure, public health surveillance, etc. Public goods tend to be intangible and many are actually information or knowledge. Private goods are normally common physical objects: drugs, MRI scanners, etc., or services such as physical examinations or rehabilitation. A second attribute of public goods is that they are not excludable. In other words, once the product is produced, it is difficult to prevent those who do not pay (free riders) from using it or benefiting from its production. By this definition, health research, knowledge, and discovery funded by the National Institutes of Health (NIH) is clearly a public good.
It is often hard to produce public goods because they represent a failure of free market forces and, as a result, are usually under produced. Although the human genome project has spawned derivative businesses to develop targeted therapeutics and genetic tests that identify risk for breast cancer, there was little incentive for individuals or businesses to develop this valuable genetic resource for the greater public good. Unless free riders can be excluded or unless the resource can somehow be monetized, there is little real incentive for businesses to participate in these grand scientific challenges. The common solution to such problems is to make government agencies responsible for production of public goods, or to have others contracted to produce them with government funding provided by taxation. Much of the early HIV/AIDS research conducted by the NIH began in the National Cancer Institute and the National Institute for Allergy and Infectious Disease. In 1988, the Office of Aids Research (OAR) was formed when it became clear that this pandemic disease required a more comprehensive strategy. This office now coordinates interagency research spanning all 27 institutes at the NIH, and its funding is directly responsible for the current therapies available to treat HIV infections and AIDS.2 The scale and complexity of response required for this one disease is an example of how valuable investments in the NIH are as the public good. The requirement to develop fundamentally new scientific knowledge, the scope of the financial investment, and the importance of sharing competitive knowledge is precisely why private industry is ill-equipped to address this and many other current challenges that exist in health research like macular degeneration or Alzheimer’s disease.
    loading  Loading Related Articles